◆ 会议时间：2026年11月6-11日
◆ 会议地点：美国 奥兰多
◆ 会议简介：
2026年美国风湿病学会(ACR)年会将于2026年11月6-11日在美国奥兰多举行。美国风湿病学会年会(ACR/ARP Annual Meeting)是世界上最大、最负盛名的的风湿病学会议，每年都有来自全球100多个国家的16000余名代表参会，ACR/ARP年会是治疗或研究关节炎、风湿和肌肉骨骼疾病患者的医生、卫生专业人员和科学家的首要教育活动，是相关人士获取最新最前沿的风湿病学研究与临床应用信息的重要平台。
美国风湿病学会（ACR）成立于1934年，是一个致力于促进风湿病学研究和风湿病治疗的非营利性会员组织。ACR在全球拥有超过8,500余名会员，包括医生、卫生专业人员、研究人员、医学生和科学家。ACR通过提供有意义的教育、研究、宣传和实践支持来促进其成员发展。未经许可禁止复制摘录转载本站任何内容-领域国际医学会议网(lingyuint.com)
ACR Convergence 2026 - American College of Rheumatology Annual Meeting
时间/Date:
November 6–11, 2026
地点/Venue:
Orlando, Florida, United States
ACR Convergence, the ACR's annual meeting, is the premier educational event for physicians, health professionals, and scientists who treat or research those with or at risk for arthritis and rheumatic and musculoskeletal diseases. The annual meeting is the leading forum for you to find the most relevant and cutting-edge rheumatology information.
摘要征文投稿-重要日期：
2026 Abstract Key Dates
April 14
Abstract Submission Site Opens
June 9, Noon ET
Abstract Submission Site Closes
August 25
Late-Breaking Abstract Submission Site Opens
Early September
Abstract Author Notification
Mid-September
Abstracts First Publication
September 22, Noon ET
Late-Breaking Abstract Submission Deadline
Mid-October
Late-Breaking Author Notification
点此提交摘要>>>Submit Abstract>>>
ACR Abstract Submission Processing Fee
The fee forsubmitting each ACR abstract is $105. The ACR accepts electronic payment only in the form of MasterCard, Visa, or American Express. Abstract processing fees must be in U.S. funds. All fees are nonrefundable—no exceptions. There are no refunds for rejected or withdrawn abstracts.
Abstract Submission Eligibility
Persons Eligible to Submit
- Members and non-members of the ACR and ARP are eligible to submit an abstract.
- Employees or owners of ineligible companies may be the presenting author of an abstract. Abstract sessions do not have CME credit.
Abstracts Eligible for Submission
- Abstracts that have been previously accepted and/or presented at other medical meetings and published in conference proceedings (“encore” abstracts) are eligible for submission. These abstracts will go through the same peer review process as any other abstracts.
- Abstracts describing original basic and clinical science related to the broad area of rheumatic diseases may be submitted.
- Abstracts reporting results of a clinical trial will be required to identify the trial phase.
- Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
Abstracts Not Eligible for Submission
- Abstracts should not report results that have been previously presented at an ACR/ARP annual meeting.
- An abstract is ineligible for consideration if it reports work that has been accepted for publication as a manuscript (e.g., full-length article, brief report, case report, concise communication or letter to the editor, etc.) prior to the submission deadline of June 9, noon ET.
- Multiple abstracts may not be submitted for one study unless substantially different research questions are being addressed in each abstract.
- Abstracts submitted for the ARP program may not be concurrently submitted to the ACR program.
- Case reports are not considered appropriate and will not be reviewed. We encourage those with interesting cases or images to consider submission to the Thieves Market, Image Competition or Global Rheumatology Summit. See separate submission processes.
- Abstracts not accepted in the main abstract review submission should not be re-submitted to the late-breaking category.
◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。
|
